Prolonged Survival in Peritoneal Metastatic Appendiceal Carcinoma Patients Treated With Combined Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

被引:2
|
作者
Acs, Miklos [1 ,5 ]
Gerken, Michael [2 ]
Zustin, Jozef [3 ,4 ]
Blaj, Sebastian [1 ]
Isgandarova, Sabina [1 ]
Piso, Pompiliu [1 ]
机构
[1] Hosp Barmherzige Bru, Dept Gen & Visceral Surg, Regensburg, Germany
[2] Univ Regensburg, Inst Qual Management & Hlth Serv Res, Tumor Ctr, Regensburg, Germany
[3] Univ Med Ctr Muenster, Gerhard Domagk Inst Pathol, Munster, Germany
[4] Inst Pathol Regensburg, Regensburg, Germany
[5] Hosp Barmherzige Bru, Dept Gen & Visceral Surg, Prufeninger Str 86, D-93049 Regensburg, Germany
关键词
Appendix carcinoma; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Peritoneal metastases; LYMPH-NODE METASTASIS; SIGNET-RING CELLS; PSEUDOMYXOMA PERITONEI; MUCINOUS ADENOCARCINOMA; NEOPLASMS; CLASSIFICATION; DISSEMINATION; DIAGNOSIS; FEATURES; OUTCOMES;
D O I
10.1016/j.jss.2022.10.083
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Primary treatment for peritoneal dissemination of appendiceal cancer is the combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. The endpoints were overall survival and evaluation of prognostic factors.Methods: Clinicopathological and treatment-related factors were obtained from a pro-spective database. A total of 84 patients, 55 (65%) primary and 29 (35%) recurrent malignant appendiceal carcinomas with synchronous and metachronous peritoneal metastases, underwent multimodal treatment between 2011 and 2021. The endpoints of the study were overall survival and evaluation of prognostic factors.Results: The median follow-up was 4.8 y; the mean age was 54.5 y (range 25-77), with a sex distribution of 69% female and 31% male. The mean peritoneal cancer index was 11.3. The proportion of mucinous, intestinal-type, signet ring cell, and goblet cell carcinoma was 56%, 23%, 11%, and 10%, respectively. The 5-y survival rate of the whole cohort was 56.7%. In primary and recurrent diseases, the overall median survival was 8.4 and 4.9 y. Signifi-cantly improved survival was detected after complete cytoreduction resection (hazard ratio [HR] for CCR-2 versus CCR-0: 9.388, 95% confidence interval [CI] 3.026-29.124, P = 0.001) and initial local operation with undelayed admission to the center (HR 0.262, 95% CI 0.089-0.773; P = 0.015). The five independent factors in Kaplan-Meier analysis and univariable Cox regression analysis associated with significant adverse survival were cancer antigen (CA) 19-9 over 37 IU/mL, signet ring cell and intestinal-type histology, positive nodal status, grading, and peritoneal cancer index >20. Neoadjuvant chemotherapy administration did not impact survival (HR 1.220, 95% CI 0.612-2.432, P = 0.571).Conclusions: With multimodal treatment, prolonged survival is attainable in stage IV pri-mary and recurrent appendiceal carcinoma with peritoneal dissemination. Direct referral to specialized centers after confirmation of peritoneal metastasis is recommended because prompt definitive treatment may significantly improve survival.& COPY; 2022 Elsevier Inc. All rights reserved.
引用
收藏
页码:839 / 852
页数:14
相关论文
共 50 条
  • [41] Combined Laparoscopic Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in a Patient with Peritoneal Mesothelioma
    Esquivel, Jesus
    Averbach, Andrew
    JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES, 2009, 19 (04): : 505 - 507
  • [42] Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival
    Gilani, Syeda Nadia Shah
    Mehta, Akash
    Garcia-Fadrique, Alfonso
    Rowaiye, Babatunde
    Jenei, Veronika
    Dayal, Sanjeev
    Chandrakumaran, Kandiah
    Carr, Norman
    Mohamed, Faheez
    Cecil, Tom
    Moran, Brendan
    INTERNATIONAL JOURNAL OF HYPERTHERMIA, 2018, 34 (05) : 578 - 584
  • [43] Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion
    Deraco, M
    Casali, P
    Inglese, MG
    Baratti, D
    Pennacchioli, E
    Bertulli, R
    Kusamura, S
    JOURNAL OF SURGICAL ONCOLOGY, 2003, 83 (03) : 147 - 153
  • [44] Predictive and Prognostic Survival Factors in Peritoneal Carcinomatosis from Appendiceal Cancer After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Jimenez, William
    Sardi, Armando
    Nieroda, Carol
    Sittig, Michelle
    Milovanov, Vladimir
    Nunez, Maria
    Aydin, Nail
    Gushchin, Vadim
    ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (13) : 4218 - 4225
  • [45] Systemic Inflammatory Markers: Predictors for Early Morbidity and Survival in Appendiceal Cancer Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Iugai, Sergei
    King, Mary Caitlin
    Kovalik, Vlaislav
    Zuniga, Luis Felipe Falk
    Pawlikowski, Kathleen
    Nieroda, Carol
    Gushchin, Vadim
    Sardi, Armando
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S231 - S232
  • [46] Predictive and Prognostic Survival Factors in Peritoneal Carcinomatosis from Appendiceal Cancer After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    William Jimenez
    Armando Sardi
    Carol Nieroda
    Michelle Sittig
    Vladimir Milovanov
    Maria Nunez
    Nail Aydin
    Vadim Gushchin
    Annals of Surgical Oncology, 2014, 21 : 4218 - 4225
  • [47] Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis
    Rihuete Caro, Cristina
    Manzanedo, Israel
    Pereira, Fernando
    Carrion-Alvarez, Lucia
    Serrano, Angel
    Perez-Viejo, Estibalitz
    EJSO, 2018, 44 (11): : 1805 - 1810
  • [48] Survival Analysis and Recurrence Patterns in 555 Patients with Colorectal Peritoneal Metastases Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Allievi, Niccolo
    Sidhom, Mark
    Samuel, Mark Vasanth
    Tzivanakis, Alexios
    Dayal, Sanjeev
    Cecil, Tom
    Mohamed, Faheez
    Moran, Brendan
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (13) : 8585 - 8595
  • [49] Outcomes of Neoadjuvant Chemotherapy for Patients with Appendiceal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Beal, E. W.
    Chen, J.
    Ahmed, A.
    Kimbrough, C.
    Grotz, T. E.
    Leiting, J. L.
    Fournier, K. F.
    Lee, A. J.
    Dineen, S.
    Dessureault, S.
    Baumgartner, J.
    Veerapong, J.
    Clarke, C. N.
    Strong, E. A.
    Maithel, S. K.
    Russell, M. C.
    Zaidi, M. Y.
    Patel, S.
    Morris, M.
    Hendrix, R. J.
    Lambert, L.
    Johnston, F. M.
    Fackche, N. T.
    Lee, B.
    Blakely, A. M.
    Abbott, D. E.
    Walle, K. Vande
    Pawlik, T. M.
    Abdel-Misih, S.
    Cloyd, J. M.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S84 - S84
  • [50] Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients
    Bakrin, N.
    Gilly, F. N.
    Baratti, D.
    Bereder, J. M.
    Quenet, F.
    Lorimier, G.
    Mohamed, F.
    Elias, D.
    Glehen, O.
    EJSO, 2013, 39 (07): : 742 - 747